Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Patient administered with vaccine past the BUD (17-Feb-2023); No adverse event; This spontaneous case was reported by a medical assistant and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient administered with vaccine past the BUD (17-Feb-2023)) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 065H22A) for COVID-19 prophylaxis.     Patient did not report any medical history or conditions, allergy, concomitant diseases and risk factor (including any previous COVID-19 diagnosis). The patient did not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient administered with vaccine past the BUD (17-Feb-2023)) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient administered with vaccine past the BUD (17-Feb-2023)) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Patient administered with vaccine past the BUD (17-Feb-2023)).    No concomitant medications were provided. The vaccines were administered between 13-Mar-2023 to 05-Jun-2023. Patients received the vaccine either as the 3rd, 4th or 5th dose. No treatment medication was provided. This case contains information for the 1st of 20 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-727723, US-MODERNATX, INC.-MOD-2023-727724, US-MODERNATX, INC.-MOD-2023-727729, US-MODERNATX, INC.-MOD-2023-727739, US-MODERNATX, INC.-MOD-2023-727744, US-MODERNATX, INC.-MOD-2023-727750, US-MODERNATX, INC.-MOD-2023-727751, US-MODERNATX, INC.-MOD-2023-727749, US-MODERNATX, INC.-MOD-2023-727755, US-MODERNATX, INC.-MOD-2023-727759, US-MODERNATX, INC.-MOD-2023-727768, US-MODERNATX, INC.-MOD-2023-727757, US-MODERNATX, INC.-MOD-2023-727770, US-MODERNATX, INC.-MOD-2023-727771, US-MODERNATX, INC.-MOD-2023-727772, US-MODERNATX, INC.-MOD-2023-727773, US-MODERNATX, INC.-MOD-2023-727775, US-MODERNATX, INC.-MOD-2023-727776, US-MODERNATX, INC.-MOD-2023-727763 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-727723:(Patient 6 Out of 20) US-MODERNATX, INC.-MOD-2023-727729:(Patient 8 Out of 20) US-MODERNATX, INC.-MOD-2023-727768:(Patient no 2 out of 20) US-MODERNATX, INC.-MOD-2023-727749:(18 patient Out of 20) US-MODERNATX, INC.-MOD-2023-727755:(19 patient Out of 20) US-MODERNATX, INC.-MOD-2023-727757:Patient no-10 out of 20 patients US-MODERNATX, INC.-MOD-2023-727744:(16 patient Out of 20) US-MODERNATX, INC.-MOD-2023-727739:(15 patient Out of 20) US-MODERNATX, INC.-MOD-2023-727724:(Patient 7 Out of 20) US-MODERNATX, INC.-MOD-2023-727751:(Patient No-9 out of 20 patients) US-MODERNATX, INC.-MOD-2023-727759:(20 patient Out of 20) US-MODERNATX, INC.-MOD-2023-727750:(17 patient Out of 20) US-MODERNATX, INC.-MOD-2023-727770:Patient no 3 out of 20 US-MODERNATX, INC.-MOD-2023-727772:(Patient No-13 out of 20 patients) US-MODERNATX, INC.-MOD-2023-727771:(Patient No-12 out of 20 patients) US-MODERNATX, INC.-MOD-2023-727775:Patient no 5 out of 20 US-MODERNATX, INC.-MOD-2023-727773:Patient no 4 out of 20 US-MODERNATX, INC.-MOD-2023-727776:(Patient No-14 out of 20 patients) US-MODERNATX, INC.-MOD-2023-727763:(Patient 11 Out of 20)